Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in 2022 and is headquartered in Waltham, MA.
相关临床试验
7
6 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2022
进行中（未招募）
4
57.1%
尚未招募
2
28.6%
招募中
1
14.3%
暂无批准数据
- AbbVie Inc. agreed to acquire Apogee Therapeutics for $135.11 per share, representing a 49.5% premium over the prior day's closing stock price. - Apogee Therapeutics is a clinical-stage biotechnology company developing novel biologics for atopic dermatitis, asthma, eosinophilic esophagitis, COPD, and other inflammatory indications. - Baron Health Care Fund sold its position in Apogee following the acquisition announcement, citing the buyout as a key contributor to the fund's favorable stock selection in biotechnology. - The acquisition underscores strong M&A activity in the biotechnology sector, driven by demand for innovative immunology and inflammation therapies.
- Apogee Therapeutics CEO Michael Henderson disposed of 95,046 shares, but 75,046 were a charitable gift to a donor-advised fund, not a market sale. - The 20,000-share open-market sale was executed under a Rule 10b5-1 trading plan adopted in August 2025, and Henderson still retains 921,000 shares worth approximately $123 million. - Lead candidate zumilokibart (APG777) posted strong 52-week Phase 2 data in atopic dermatitis with durable responses on every-3- and 6-month dosing, with Phase 3 initiation expected in the second half of 2026. - A $403 million equity raise brought cash reserves to roughly $1.3 billion, funding operations into 2029, with a head-to-head readout against Dupixent also anticipated in late 2026.
- Paul Weiss and Kirkland & Ellis are serving as legal advisors on AbbVie's $10.9 billion acquisition of Apogee Therapeutics. - The deal represents a significant transaction in the pharmaceutical M&A landscape, with two major law firms steering the process. - AbbVie's acquisition of Apogee signals continued consolidation and strategic investment in the biopharmaceutical sector. - The transaction underscores the high-value nature of current pharmaceutical dealmaking activity.
- AbbVie is reportedly nearing a deal to acquire Apogee Therapeutics for approximately $10.9 billion in cash, representing a roughly 60% premium to Apogee's closing share price. - Apogee's lead asset, zumilokibart, is a long-acting IL-13 inhibitor set to enter Phase 3 trials later this year for atopic dermatitis, positioning it as a potential competitor to Dupixent. - The acquisition would strengthen AbbVie's inflammatory disease portfolio as the company works to offset revenue losses following Humira's recent loss of patent protection. - An announcement could come as early as Monday, pending successful completion of negotiations, according to the Financial Times.
- Apogee Therapeutics reported positive interim results from a Phase 1b trial of zumilokibart (APG777) in 19 patients with mild-to-moderate asthma, demonstrating a 60% reduction in FeNO levels and durable suppression through 32 weeks. - The anti-IL-13 antibody showed a favorable safety profile with no serious adverse events, conjunctivitis, or injection site reactions, supporting potential for extended 3- to 6-month dosing intervals. - The company plans to advance zumilokibart in the ASPIRE asthma trial while continuing Phase 2 development in atopic dermatitis, with Phase 3 initiation expected by end of 2026. - Apogee maintains a strong cash position of $913 million with runway into second half of 2028, supporting advancement toward potential 2029 launch of zumilokibart.
- Over 100 pharmaceutical companies are actively developing more than 100 pipeline drugs for eczema treatment, representing a significant expansion in therapeutic options for this chronic inflammatory skin condition. - Sanofi's Amlitelimab achieved all primary and key secondary endpoints in the Phase III COAST 1 study, demonstrating statistically significant skin clearance in patients with moderate-to-severe atopic dermatitis at Week 24. - The pipeline features diverse mechanisms of action including OX40 ligand inhibitors, interleukin receptor antagonists, and STAT6 transcription factor degraders, with approximately 10+ drugs in late-stage development. - Recent clinical milestones include positive Phase I results for Concerto Biosciences' ENS-002 topical biotherapeutic and FDA clearance for Sitryx Therapeutics' SYX-5219 Phase Ib trial.
- Apogee Therapeutics completed a $345 million public offering to fund development of its inflammatory and immunology biologics portfolio. - The clinical-stage company is advancing APG777 for atopic dermatitis treatment, targeting the largest and least penetrated I&I market. - Apogee's pipeline includes four validated targets for conditions including asthma, eosinophilic esophagitis, and COPD. - The company's antibody programs use advanced engineering to optimize half-life and overcome limitations of existing therapies.
- Apogee Therapeutics announced positive interim Phase 1 results for APG333, demonstrating potential for extended 3- and 6-month dosing intervals with favorable safety data in healthy volunteers. - The company completed a $345 million public offering, significantly strengthening its financial position to fund ongoing and future clinical trials across its expanding pipeline. - Stock price surged 19.7% following the clinical update and capital raise, positioning the company to advance its immunology and inflammation disorder programs. - The strengthened cash position reduces immediate funding risk and could accelerate potential partnering opportunities or pipeline expansion initiatives.
• The moderate to severe atopic dermatitis market is experiencing significant growth with 45+ companies developing over 50 pipeline therapies, driven by rising global prevalence and increased awareness of the condition. • Recent advancements include promising biologics like rezpegaldesleukin (granted FDA fast-track designation), JAK inhibitors such as VC005 and QY201, and novel mechanisms targeting IL-4/IL-13 pathways, offering new hope for patients with inadequate response to current treatments. • Key players including Nektar Therapeutics, Corvus Pharmaceuticals, and Apogee Therapeutics are advancing clinical trials with significant milestones expected in late 2025, potentially transforming the therapeutic landscape for this chronic inflammatory skin condition.
- APG777, Apogee Therapeutics' investigational antibody for atopic dermatitis, demonstrated favorable safety profile and extended half-life in Phase 1 healthy volunteer study. - The drug candidate showed potential for monthly or less frequent dosing regimen, offering a significant advantage over existing treatments in the atopic dermatitis space. - Initial pharmacokinetic data supports further clinical development, with Phase 2 trials planned to evaluate efficacy in atopic dermatitis patients.
